Hiroshi Yamazaki

List of Publications by Year
in descending order

522	14,964	22153	39675
papers	citations	59 h-index	94 g-index

542	542	542	10661
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Comprehensive Investigation of Dog Cytochrome P450 3A (CYP3A) Reveals a Functional Role of Newly Identified CYP3A98 in Small Intestine. Drug Metabolism and Disposition, 2023, 51, 38-45.	3.3	10
2	Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes. Drug Metabolism and Disposition, 2023, 51, 123-129.	3.3	6
3	An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals. Drug Metabolism and Pharmacokinetics, 2022, 42, 100410.	2.2	19
4	Drug-oxidizing and conjugating non-cytochrome P450 (non-P450) enzymes in cynomolgus monkeys and common marmosets as preclinical models for humans. Biochemical Pharmacology, 2022, 197, 114887.	4.4	9
5	Imaging Mass Spectrometry (IMS) for drug discovery and development survey: Results on methods, applications and regulatory compliance. Drug Metabolism and Pharmacokinetics, 2022, 43, 100438.	2.2	2
6	Systematic identification and characterization of cynomolgus macaque solute carrier transporters. Drug Metabolism and Pharmacokinetics, 2022, 43, 100437.	2.2	0
7	Oxidation of 3Â´-methoxyflavone, 4Â´-methoxyflavone, and 3Â´,4Â´-dimethoxyflavone and their derivatives having 5,7-dihydroxyl moieties by human cytochromes P450 1B1 and 2A13. Xenobiotica, 2022, , 1-41.	1.1	1
8	Cytochrome P450-dependent drug oxidation activities and their expression levels in liver microsomes of chimeric TK-NOG mice with humanized livers. Drug Metabolism and Pharmacokinetics, 2022, 44, 100454.	2.2	10
9	Probe drug T-1032ÂN-oxygenation mediated by cytochrome P450 3A5 in human hepatocytes inÂvitro and in humanized-liver mice inÂvivo. Drug Metabolism and Pharmacokinetics, 2022, 44, 100453.	2.2	3
10	Comparison of mouse and human cytochrome P450 mediated-drug metabolising activities in hepatic and extrahepatic microsomes. Xenobiotica, 2022, 52, 229-239.	1.1	4
11	Trivariate Linear Regression and Machine Learning Prediction of Possible Roles of Efflux Transporters in Estimated Intestinal Permeability Values of 301 Disparate Chemicals. Biological and Pharmaceutical Bulletin, 2022, , .	1.4	2
12	Polymorphic cytochromes P450 in non-human primates. Advances in Pharmacology, 2022, , 329-364.	2.0	1
13	Cytochrome P450 2J Genes Are Expressed in Dogs, Cats, and Pigs, and Encode Functional Drug-Metabolizing Enzymes. Drug Metabolism and Disposition, 2022, 50, 1434-1441.	3.3	6
14	Further survey of genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects found in an updated database of genome resources and identified by phenotyping for trimethylaminuria. Drug Metabolism and Pharmacokinetics, 2022, 46, 100465.	2.2	4
15	Molecular and functional characterization of flavin-containing monooxygenases in pigs, dogs, and cats. Biochemical Pharmacology, 2022, 202, 115125.	4.4	18
16	Molecular and Functional Characterization of N-Acetyltransferases in Common Marmosets and Pigs. Drug Metabolism and Disposition, 2022, 50, 1429-1433.	3.3	1
17	Plasma and synovial fluid concentrations of linezolid in patients with knee osteoarthritis infected with Staphylococcus aureus. Journal of Pharmaceutical Health Care and Sciences, 2022, 8, .	1.0	0
18	Liquid chromatography-tandem mass spectrometry analysis of oxidation of 2â€²-, 3â€²-, 4â€²- and 6-hydroxyflavanones by human cytochrome P450 enzymes. Xenobiotica, 2021, 51, 139-154.	1.1	4

#	Article	IF	Citations
19	Evaluation of domain of unknown function 1220 (DUF1220) for detection of human genome by quantitative polymerase chain reaction: Potential use in assessing the biodistribution of transplanted therapeutic human cells. Drug Metabolism and Pharmacokinetics, 2021, 38, 100366.	2.2	0
20	Plasma and hepatic concentrations of acetaminophen and its primary conjugates after oral administrations determined in experimental animals and humans and extrapolated by pharmacokinetic modeling. Xenobiotica, 2021, 51, 316-323.	1.1	4
21	InÂvivo drug interactions of itopride and trimethylamine mediated by flavin-containing monooxygenase 3 in humanized-liver mice. Drug Metabolism and Pharmacokinetics, 2021, 37, 100369.	2.2	4
22	Metabolic Profiles of Tetrabromobisphenol A in Humans Extrapolated from Humanized-Liver Mouse Data Using a Simplified Physiologically Based Pharmacokinetic Model. Chemical Research in Toxicology, 2021, 34, 522-528.	3.3	8
23	Genetic variants of UDP-glucuronosyltransferases 1A1, 1A6, and 1A9 in cynomolgus and rhesus macaques. Xenobiotica, 2021, 51, 115-121.	1.1	1
24	Metabolic activation and deactivation of dietary-derived coumarin mediated by cytochrome P450 enzymes in rat and human liver preparations. Journal of Toxicological Sciences, 2021, 46, 371-378.	1.5	7
25	Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19. Xenobiotica, 2021, 51, 479-493.	1.1	3
26	Pharmacokinetics of primary oxidative metabolites of thalidomide in rats and in chimeric mice humanized with different human hepatocytes. Journal of Toxicological Sciences, 2021, 46, 311-317.	1.5	7
27	Genetic variants of aldehyde oxidase (AOX) 1 in cynomolgus and rhesus macaques. Xenobiotica, 2021, 51, 494-499.	1.1	1
28	Differences in pharmacokinetics and haematotoxicities of aniline and its dimethyl derivatives orally administered in rats. Biological and Pharmaceutical Bulletin, 2021, 44, 1775-1780.	1.4	3
29	In Silico Prediction of Input Parameters for Simplified Physiologically Based Pharmacokinetic Models for Estimating Plasma, Liver, and Kidney Exposures in Rats after Oral Doses of 246 Disparate Chemicals. Chemical Research in Toxicology, 2021, 34, 507-513.	3.3	23
30	Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 6.	1.0	9
31	Methyl-hydroxylation and subsequent oxidation to produce carboxylic acid is the major metabolic pathway of tolbutamide in chimeric TK-NOG mice transplanted with human hepatocytes. Xenobiotica, 2021, 51, 582-589.	1.1	12
32	Predicted Contributions of Flavin-containing Monooxygenases to the N-oxygenation of Drug Candidates Based on their Estimated Base Dissociation Constants. Current Drug Metabolism, 2021, 22, 208-214.	1.2	5
33	Hepatotoxicological potential of P-toluic acid in humanised-liver mice investigated using simplified physiologically based pharmacokinetic models. Xenobiotica, 2021, 51, 1-7.	1.1	2
34	Differences in Hydrolase Activities in the Liver and Small Intestine between Marmosets and Humans. Drug Metabolism and Disposition, 2021, 49, 718-728.	3.3	3
35	Genetic variants of flavin-containing monooxygenase 3 (FMO3) in Japanese subjects identified by phenotyping for trimethylaminuria and found in a database of genome resources. Drug Metabolism and Pharmacokinetics, 2021, 38, 100387.	2.2	10
36	Effects of polymorphic cytochrome P450 2A6 genotypes on chemoprevention against colorectal tumors in single Japanese cohort using daily low-dose aspirin: insights into future personalized treatments. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 26.	1.0	3

#	Article	IF	Citations
37	Roles of cytochrome P450 2A6 in the oxidation of flavone, 4â€²-hydroxyflavone, and 4â€²-, 3â€²-, and 2â€²-methoxyflavones by human liver microsomes. Xenobiotica, 2021, 51, 995-1009.	1.1	6
38	Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam. Drug Metabolism and Pharmacokinetics, 2021, 39, 100394.	2.2	5
39	Cloning, sequence analysis, and tissue expression of marmoset paraoxonase 1. Drug Metabolism and Pharmacokinetics, 2021, 39, 100398.	2.2	0
40	Oxidative metabolism and pharmacokinetics of the EGFR inhibitor BIBX1382 in chimeric NOG-TKm30 mice transplanted with human hepatocytes. Drug Metabolism and Pharmacokinetics, 2021, 41, 100419.	2.2	8
41	Pharmacokinetic modeling of over-the-counter drug diphenhydramine self-administered in overdoses in Japanese patients admitted to hospital. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 32.	1.0	5
42	An Updated In Silico Prediction Method for Volumes of Systemic Circulation of 323 Disparate Chemicals for Use in Physiologically Based Pharmacokinetic Models to Estimate Plasma and Tissue Concentrations after Oral Doses in Rats. Chemical Research in Toxicology, 2021, 34, 2180-2183.	3.3	9
43	Pharmacokinetics of loxoprofen in a self-administered overdose in a Japanese patient admitted to hospital. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 33.	1.0	5
44	A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects. Drug Metabolism and Pharmacokinetics, 2021, 41, 100420.	2.2	7
45	UDP-glucuronosyltransferase 1A4-mediated N2-glucuronidation is the major metabolic pathway of lamotrigine in chimeric NOG-TKm30 mice with humanised-livers. Xenobiotica, 2021, 51, 1146-1154.	1.1	4
46	Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes. Drug Metabolism and Pharmacokinetics, 2021, 40, 100412.	2.2	3
47	Prediction of permeability across intestinal cell monolayers for 219 disparate chemicals using in vitro experimental coefficients in a pH gradient system and in silico analyses by trivariate linear regressions and machine learning. Biochemical Pharmacology, 2021, 192, 114749.	4.4	14
48	Metabolic profiles for the pyrrolizidine alkaloid neopetasitenine and its metabolite petasitenine in humans extrapolated from rat <i>in vivo</i> and <i>in vitro</i> data sets using a simplified physiologically based pharmacokinetic model. Journal of Toxicological Sciences, 2021, 46, 391-399.	1.5	8
49	Pharmacokinetics of caffeine self-administered in overdose in a Japanese patient admitted to hospital. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 36.	1.0	4
50	Machine Learning Prediction of the Three Main Input Parameters of a Simplified Physiologically Based Pharmacokinetic Model Subsequently Used to Generate Time-Dependent Plasma Concentration Data in Humans after Oral Doses of 212 Disparate Chemicals. Biological and Pharmaceutical Bulletin, 2021, , .	1.4	12
51	Roles of human cytochrome P450 1A2 in coumarin 3,4-epoxidation mediated by untreated hepatocytes and by those metabolically inactivated with furafylline in previously transplanted chimeric mice. Journal of Toxicological Sciences, 2021, 46, 525-530.	1.5	6
52	Cloning and tissue expression of ATP-binding cassette transporters in cynomolgus macaques. Drug Metabolism and Pharmacokinetics, 2021, 42, 100431.	2.2	0
53	Pharmacokinetics of primary metabolites 5-hydroxythalidomide and 5â€²-hydroxythalidomide formed after oral administration of thalidomide in the rabbit, a thalidomide-sensitive species. Journal of Toxicological Sciences, 2021, 46, 553-560.	1.5	3
54	Plasma concentration profiles for hepatotoxic pyrrolizidine alkaloid senkirkine in humans extrapolated from rat data sets using a simplified physiologically based pharmacokinetic model. Drug Metabolism Letters, 2021, 15, .	0.8	2

#	Article	IF	Citations
55	Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6. Drug Metabolism and Pharmacokinetics, 2020, 35, 191-200.	2.2	9
56	Predicting successful/unsuccessful extrapolation for in vivo total clearance of model compounds with a variety of hepatic intrinsic metabolism and protein bindings in humans from pharmacokinetic data using chimeric mice with humanised liver. Xenobiotica, 2020, 50, 526-535.	1.1	5
57	Expression levels of microRNAs that are potential cytochrome P450 regulators in cynomolgus macaques. Xenobiotica, 2020, 50, 747-752.	1.1	2
58	Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes. Xenobiotica, 2020, 50, 733-740.	1.1	12
59	Different Roles of Human Cytochrome P450 2C9 and 3A Enzymes in Diclofenac 4â€²- and 5-Hydroxylations Mediated by Metabolically Inactivated Human Hepatocytes in Previously Transplanted Chimeric Mice. Chemical Research in Toxicology, 2020, 33, 634-639.	3.3	8
60	Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment. Xenobiotica, 2020, 50, 1023-1031.	1.1	5
61	Cloning and tissue expression of cytochrome P450 2S1, 4V2, 7A1, 7B1, 8B1, 24A1, 26A1, 26C1, 27A1, 39A1, and 51A1 in marmosets. Drug Metabolism and Pharmacokinetics, 2020, 35, 244-247.	2.2	1
62	Molecular characterization of functional UDP-glucuronosyltransferases 1A and 2B in common marmosets. Biochemical Pharmacology, 2020, 172, 113748.	4.4	9
63	The marmoset cytochrome P450 superfamily: Sequence/phylogenetic analyses, genomic structure, and catalytic function. Biochemical Pharmacology, 2020, 171, 113721.	4.4	13
64	Prediction of circulating human metabolites of pemafibrate, a novel antidyslipidemic drug, using chimeric mice with humanized liver. Xenobiotica, 2020, 50, 769-775.	1.1	4
65	Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital. Journal of Pharmaceutical Health Care and Sciences, 2020, 6, 20.	1.0	7
66	Expression of functional sulfotransferases (SULT) 1A1, 1A3, 1B1, 1C2, 1E1, and 2A1 in common marmosets. Biochemical Pharmacology, 2020, 180, 114189.	4.4	6
67	Regional distributions of UDP-glucuronosyltransferase activities toward estradiol and serotonin in the liver and small intestine of cynomolgus macaques. Drug Metabolism and Pharmacokinetics, 2020, 35, 401-404.	2.2	0
68	Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations. Xenobiotica, 2020, 50, 1413-1422.	1.1	0
69	Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by inÂvivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling. Drug Metabolism and Pharmacokinetics, 2020, 35, 505-514.	2.2	3
70	Molecular cloning, sequence analysis, and tissue distribution of marmoset monoamine oxidases A and B. Drug Metabolism and Pharmacokinetics, 2020, 35, 479-482.	2.2	3
71	Molecular characterization of UDP-glucuronosyltransferases 3A and 8A in cynomolgus macaques. Drug Metabolism and Pharmacokinetics, 2020, 35, 397-400.	2.2	2
72	Trimethylamine N-oxygenation in cynomolgus macaques genotyped for flavin-containing monooxygenase 3 (FMO3). Drug Metabolism and Pharmacokinetics, 2020, 35, 571-573.	2.2	3

#	Article	IF	Citations
73	Different Hepatic Concentrations of Bromobenzene, 1,2-Dibromobenzene, and 1,4-Dibromobenzene in Humanized-Liver Mice Predicted Using Simplified Physiologically Based Pharmacokinetic Models as Putative Markers of Toxicological Potential. Chemical Research in Toxicology, 2020, 33, 3048-3053.	3.3	7
74	Human Aldehyde Oxidase 1â€“Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes. Drug Metabolism and Disposition, 2020, 48, 580-586.	3.3	13
75	Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data. Drug Metabolism and Pharmacokinetics, 2020, 35, 389-396.	2.2	4
76	Novel variants in outer protein surface of flavin-containing monooxygenase 3 found in an Argentinian case with impaired capacity for trimethylamine N-oxygenation. Drug Metabolism and Pharmacokinetics, 2020, 35, 383-388.	2.2	2
77	Molecular cloning and tissue distribution of marmoset thiopurine S-methyltransferase. Drug Metabolism and Pharmacokinetics, 2020, 35, 475-478.	2.2	0
78	Physiologically Based Pharmacokinetic Models Predicting Renal and Hepatic Concentrations of Industrial Chemicals after Virtual Oral Doses in Rats. Chemical Research in Toxicology, 2020, 33, 1736-1751.	3.3	27
79	Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1. Drug Metabolism and Pharmacokinetics, 2020, 35, 354-360.	2.2	7
80	Interleukin-1Î² and tumor necrosis factor-Î± affect cytochrome P450 expression in cynomolgus macaque hepatocytes. Drug Metabolism and Pharmacokinetics, 2020, 35, 341-343.	2.2	4
81	Systematic characterization of glutathione S-transferases in common marmosets. Biochemical Pharmacology, 2020, 174, 113835.	4.4	8
82	mRNA levels of drug-metabolizing enzymes in 11 brain regions of cynomolgus macaques. Drug Metabolism and Pharmacokinetics, 2020, 35, 248-252.	2.2	2
83	Genetic variants of N-acetyltransferases 1 and 2 (NAT1 and NAT2) in cynomolgus and rhesus macaques. Biochemical Pharmacology, 2020, 177, 113996.	4.4	7
84	Preference forO-demethylation reactions in the oxidation of 2â€²-, 3â€²-, and 4â€²-methoxyflavones by human cytochrome P450 enzymes. Xenobiotica, 2020, 50, 1158-1169.	1.1	8
85	Determination and prediction of permeability across intestinal epithelial cell monolayer of a diverse range of industrial chemicals/drugs for estimation of oral absorption as a putative marker of hepatotoxicity. Toxicology Reports, 2020, 7, 149-154.	3.3	36
86	Metabolic profiles of coumarin in human plasma extrapolated from a rat data set with a simplified physiologically based pharmacokinetic model. Journal of Toxicological Sciences, 2020, 45, 695-700.	1.5	9
87	Plasma, liver, and kidney exposures in rats after oral doses of industrial chemicals predicted using physiologically based pharmacokinetic models: A case study of perï¬‚uorooctane sulfonic acid. Journal of Toxicological Sciences, 2020, 45, 763-767.	1.5	4
88	Different Effects of Polymorphic Flavin-Containing Monooxygenase 3 and Cytochrome P450 2A6 Activities on an Index of Arteriosclerosis as a Lifestyle-Related Disease in a General Population in Japan. Current Drug Metabolism, 2020, 21, 1161-1164.	1.2	2
89	Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes. Xenobiotica, 2019, 49, 791-802.	1.1	10
90	Suitable albumin concentrations for enhanced drug oxidation activities mediated by human liver microsomal cytochrome P450 2C9 and other forms predicted with unbound fractions and partition/distribution coefficients of model substrates. Xenobiotica, 2019, 49, 557-562.	1.1	8

#	Article	IF	Citations
91	Expression and inducibility of cytochrome P450s in human hepatocytes isolated from chimeric mice with humanised livers. Xenobiotica, 2019, 49, 678-687.	1.1	13
92	In vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions. Xenobiotica, 2019, 49, 961-969.	1.1	4
93	In vivo hepatic clearance of lipophilic drugs predicted by in vitro uptake data into cryopreserved hepatocytes suspended in sera of rats, guinea pigs, monkeys and humans. Xenobiotica, 2019, 49, 887-894.	1.1	6
94	Human urinary concentrations of monoisononyl phthalate estimated using physiologically based pharmacokinetic modeling and experimental pharmacokinetics in humanized-liver mice orally administered with diisononyl phthalate. Xenobiotica, 2019, 49, 513-520.	1.1	7
95	Human plasma and liver concentrations of styrene estimated by combining a simple physiologically based pharmacokinetic model with rodent data. Journal of Toxicological Sciences, 2019, 44, 543-548.	1.5	10
96	Genetic variants of flavin-containing monooxygenase 3 (FMO3) derived from Japanese subjects with the trimethylaminuria phenotype and whole-genome sequence data from a large Japanese database. Drug Metabolism and Pharmacokinetics, 2019, 34, 334-339.	2.2	13
97	Comparison of Steroid Hormone Hydroxylations by and Docking to Human Cytochromes P450 3A4 and 3A5. Journal of Pharmacy and Pharmaceutical Sciences, 2019, 22, 332-339.	2.1	14
98	Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharmaceutics and Drug Disposition, 2019, 40, 350-357.	1.9	11
99	Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes. Biopharmaceutics and Drug Disposition, 2019, 40, 62-69.	1.9	9
100	Editorial. Regulatory Toxicology and Pharmacology, 2019, 101, A1-A2.	2.7	0
101	Survey of Drug Oxidation Activities in Hepatic and Intestinal Microsomes of Individual Common Marmosets, a New Nonhuman Primate Animal Model. Current Drug Metabolism, 2019, 20, 103-113.	1.2	7
102	Molecular and functional characterization of cytosolic sulfotransferases in cynomolgus macaque. Biochemical Pharmacology, 2019, 166, 153-162.	4.4	11
103	Expression and induction ability of cytochrome P450 in human hepatocytes isolated from chimeric mice with humanized livers. Drug Metabolism and Pharmacokinetics, 2019, 34, S44.	2.2	0
104	Mutations of flavin-containing monooxygenase 3 (FMO3) gene in Japanese cohorts. Drug Metabolism and Pharmacokinetics, 2019, 34, S63.	2.2	1
105	Functional and molecular characterization of UDP-glucuronosyltransferase 2 family in cynomolgus macaques. Biochemical Pharmacology, 2019, 163, 335-344.	4.4	12
106	Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chemico-Biological Interactions, 2019, 306, 1-9.	4.0	15
107	Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes. Chemical Research in Toxicology, 2019, 32, 1268-1280.	3.3	11
108	Functionally relevant genetic variants of glutathione S-transferase GSTM5 in cynomolgus and rhesus macaques. Xenobiotica, 2019, 49, 995-1000.	1.1	6

#	Article	IF	Citations
109	Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital. Xenobiotica, 2019, 49, 1001-1006.	1.1	5
110	Non-synonymous genetic variants of flavin-containing monooxygenase 3 (FMO3) in cynomolgus macaques. Drug Metabolism and Pharmacokinetics, 2019, 34, 104-107.	2.2	6
111	Predictability of human pharmacokinetics of diisononyl phthalate (DINP) using chimeric mice with humanized liver. Xenobiotica, 2019, 49, 1311-1322.	1.1	2
112	Regioselective hydroxylation of an antiarrhythmic drug, propafenone, mediated by rat liver cytochrome P450 2D2 differs from that catalyzed by human P450 2D6. Xenobiotica, 2019, 49, 1323-1331.	1.1	5
113	Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals. Drug Metabolism and Disposition, 2019, 47, 114-123.	3.3	18
114	Steady-State Human Pharmacokinetics of Monobutyl Phthalate Predicted by Physiologically Based Pharmacokinetic Modeling Using Single-Dose Data from Humanized-Liver Mice Orally Administered with Dibutyl Phthalate. Chemical Research in Toxicology, 2019, 32, 333-340.	3.3	18
115	Novel variants and haplotypes of human flavin-containing monooxygenase 3 gene associated with Japanese subjects suffering from trimethylaminuria. Xenobiotica, 2019, 49, 1244-1250.	1.1	11
116	Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferatorâ€activated receptorâ€alpha modulator, in rats and monkeys. Biopharmaceutics and Drug Disposition, 2019, 40, 12-17.	1.9	10
117	Plasma and Hepatic Concentrations of Chemicals after Virtual Oral Administrations Extrapolated Using Rat Plasma Data and Simple Physiologically Based Pharmacokinetic Models. Chemical Research in Toxicology, 2019, 32, 211-218.	3.3	38
118	Expression and metabolic activity of flavinâ€containing monooxygenase 1 in cynomolgus macaque kidney. Journal of Medical Primatology, 2019, 48, 51-53.	0.6	3
119	Marmoset cytochrome P450 2B6, a propofol hydroxylase expressed in liver. Xenobiotica, 2019, 49, 265-269.	1.1	5
120	Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver. Xenobiotica, 2019, 49, 404-414.	1.1	15
121	Importance of cynomolgus monkeys in development of monoclonal antibody drugs. Drug Metabolism and Pharmacokinetics, 2019, 34, 55-63.	2.2	27
122	Cytochrome P450 2A6 and other human P450 enzymes in the oxidation of flavone and flavanone. Xenobiotica, 2019, 49, 131-142.	1.1	15
123	Extrapolation of Hepatic Concentrations of Industrial Chemicals Using Pharmacokinetic Models to Predict Hepatotoxicity. Toxicological Research, 2019, 35, 295-301.	2.1	5
124	Polymorphisms of cytochrome P450 2B6 (<scp>CYP</scp>2B6) in cynomolgus and rhesus macaques. Journal of Medical Primatology, 2018, 47, 232-237.	0.6	0
125	In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. Biochemical Pharmacology, 2018, 152, 272-278.	4.4	16
126	Genetic polymorphisms of drug-metabolizing cytochrome P450 enzymes in cynomolgus and rhesus monkeys and common marmosets in preclinical studies for humans. Biochemical Pharmacology, 2018, 153, 184-195.	4.4	23

#	Article	IF	Citations
127	Chimeric mice with humanized liver as a model for testing organophosphate and carbamate pesticide exposure. Pest Management Science, 2018, 74, 1424-1430.	3.4	17
128	Terfenadine t-butyl hydroxylation catalyzed by human and marmoset cytochrome P450 3A and 4F enzymes in livers and small intestines. Xenobiotica, 2018, 48, 342-347.	1.1	5
129	Human plasma metabolic profiles of benzydamine, a flavin-containing monooxygenase probe substrate, simulated with pharmacokinetic data from control and humanized-liver mice. Xenobiotica, 2018, 48, 117-123.	1.1	9
130	Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants. Xenobiotica, 2018, 48, 565-575.	1.1	13
131	Marmoset pulmonary cytochrome P450 2F1 oxidizes biphenyl and 7-ethoxycoumarin and hepatic human P450 substrates. Xenobiotica, 2018, 48, 656-662.	1.1	7
132	Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. Xenobiotica, 2018, 48, 720-726.	1.1	11
133	Association with polymorphic marmoset cytochrome P450 2C19 of in vivo hepatic clearances of chirally separated R-omeprazole and S-warfarin using individual marmoset physiologically based pharmacokinetic models. Xenobiotica, 2018, 48, 1072-1077.	1.1	8
134	Molecular cloning and tissue distribution of a novel marmoset ABC transporter. Biopharmaceutics and Drug Disposition, 2018, 39, 59-63.	1.9	3
135	Expression of cytochrome P450 regulators in cynomolgus macaque. Xenobiotica, 2018, 48, 695-703.	1.1	3
136	In vivo Analysis of the Anti-atrial Fibrillatory, Proarrhythmic and Cardiodepressive Profiles of Dronedarone as a Guide for Safety Pharmacological Evaluation of Antiarrhythmic Drugs. Cardiovascular Toxicology, 2018, 18, 242-251.	2.7	9
137	Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies. Biopharmaceutics and Drug Disposition, 2018, 39, 116-121.	1.9	11
138	Progesterone hydroxylation by cytochromes P450 2C and 3A enzymes in marmoset liver microsomes. Xenobiotica, 2018, 48, 757-763.	1.1	9
139	R-warfarin clearances from plasma associated with polymorphic cytochrome P450 2C19 and simulated by individual physiologically based pharmacokinetic models for 11 cynomolgus monkeys. Xenobiotica, 2018, 48, 206-210.	1.1	8
140	Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques. Chemical Research in Toxicology, 2018, 31, 1373-1381.	3.3	8
141	Molecular and Functional Characterization of N-Acetyltransferases NAT1 and NAT2 in Cynomolgus Macaque. Chemical Research in Toxicology, 2018, 31, 1269-1276.	3.3	13
142	Genetic Variants of Glutathione S-Transferase GSTT1 and GSTT2 in Cynomolgus Macaques: Identification of GSTT Substrates and Functionally Relevant Alleles. Chemical Research in Toxicology, 2018, 31, 1086-1091.	3.3	8
143	Dihydrocodeine Overdoses in a Neonate and in a 14-year-old Girl Who Were Both Genotyped as Cytochrome P450 2D6*1/*10-*36: Comparing Developmental Ages and Drug Monitoring Data With the Results of Pharmacokinetic Modeling. Therapeutic Drug Monitoring, 2018, 40, 162-165.	2.0	9
144	Molecular and functional characterization of UDP-glucuronosyltransferase 1A in cynomolgus macaques. Biochemical Pharmacology, 2018, 155, 172-181.	4.4	10

#	Article	IF	Citations
145	Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA. Journal of Toxicological Sciences, 2018, 43, 369-375.	1.5	11
146	Improved Intranasal Retentivity and Transnasal Absorption Enhancement by PEGylated Poly-l-ornithine. Pharmaceuticals, 2018, 11, 9.	3.8	9
147	Obfuscating transparency?. Regulatory Toxicology and Pharmacology, 2018, 97, A1-A3.	2.7	2
148	Cytochrome P450-dependent drug oxidation activities in commercially available hepatocytes derived from human induced pluripotent stem cells cultured for 3 weeks. Journal of Toxicological Sciences, 2018, 43, 241-245.	1.5	8
149	Collaborative Method Performance Study of the Measurement of Nicotine, Its Metabolites, and Total Nicotine Equivalents in Human Urine. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1083-1090.	2.5	15
150	Human plasma concentrations of trimethylamine N-oxide extrapolated using pharmacokinetic modeling based on metabolic profiles of deuterium-labeled trimethylamine in humanized-liver mice. Journal of Toxicological Sciences, 2018, 43, 387-393.	1.5	5
151	CYP2C76 deficiency is embryonic lethal in cynomolgus macaques: The potential role of CYP2C76 in early embryogenesis. Drug Metabolism and Pharmacokinetics, 2017, 32, 112-115.	2.2	0
152	Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone. Drug Metabolism and Disposition, 2017, 45, 457-467.	3.3	23
153	Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects. International Journal of Food Sciences and Nutrition, 2017, 68, 1013-1020.	2.8	9
154	Molecular Cloning and Characterization of Marmoset Aldehyde Oxidase. Drug Metabolism and Disposition, 2017, 45, 883-886.	3.3	9
155	Functional characterization and tissue expression of marmoset cytochrome P450 2E1. Biopharmaceutics and Drug Disposition, 2017, 38, 394-397.	1.9	6
156	Efavirenz clearances in vitro and in vivo in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models. Biopharmaceutics and Drug Disposition, 2017, 38, 439-442.	1.9	5
157	Regio- and Stereo-Selective Oxidation of a Cardiovascular Drug, Metoprolol, Mediated by Cytochrome P450 2D and 3A Enzymes in Marmoset Livers. Drug Metabolism and Disposition, 2017, 45, 896-899.	3.3	11
158	Comparison of catalytic and inhibitory properties in human drug-metabolizing cytochrome P450 3A4 and 3A5 for various compounds including endogenous steroid hormones and azole antifungals by molecular docking simulation. Drug Metabolism and Pharmacokinetics, 2017, 32, S38.	2.2	1
159	Identification and characterization of cytochrome P450 4F enzymes in marmosets. Drug Metabolism and Pharmacokinetics, 2017, 32, S40.	2.2	0
160	Human plasma concentration-time profiles of troglitazone and troglitazone sulfate estimated by in vivo experiments with chimeric mice wth humanized livers. Drug Metabolism and Pharmacokinetics, 2017, 32, S76.	2.2	0
161	Characterization of microminipigs as an inÂvivo experimental model for cardiac safety pharmacology. Journal of Pharmacological Sciences, 2017, 133, 103-109.	2.5	10
162	Marmoset Flavin-Containing Monooxygenase 3 in the Liver Is a Major Benzydamine and Sulindac Sulfide Oxygenase. Drug Metabolism and Disposition, 2017, 45, 497-500.	3.3	8

#	Article	IF	Citations
163	Hepatic expression of cytochrome P450 enzymes in nonâ€human primate species. Journal of Medical Primatology, 2017, 46, 347-351.	0.6	1
164	The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage. Chemical Research in Toxicology, 2017, 30, 1622-1628.	3.3	31
165	Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-Metabolizing Enzymes. Chemical Research in Toxicology, 2017, 30, 53-60.	3.3	9
166	Sex- and age-dependent gene expression in human liver: An implication for drug-metabolizing enzymes. Drug Metabolism and Pharmacokinetics, 2017, 32, 100-107.	2.2	20
167	Marmoset cytochrome P450 4A11, a novel arachidonic acid and lauric acid ï‰-hydroxylase expressed in liver and kidney tissues. Xenobiotica, 2017, 47, 553-561.	1.1	16
168	Simulation of human plasma concentrationâ€“time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. Xenobiotica, 2017, 47, 382-393.	1.1	26
169	Stable and episodic/bolus patterns of methylmercury exposure on mercury accumulation and histopathologic alterations in the nervous system. Environmental Research, 2017, 152, 446-453.	7.5	9
170	Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice. Xenobiotica, 2017, 47, 844-848.	1.1	20
171	Cloning and expression of a novel catechol-O-methyltransferase in common marmosets. Journal of Veterinary Medical Science, 2017, 79, 267-272.	0.9	3
172	Human plasma and urinary metabolic profiles of trimethylamine and trimethylamine <i>N</i>-oxide extrapolated using a simple physiologically based pharmacokinetic model. Journal of Toxicological Sciences, 2017, 42, 485-490.	1.5	5
173	Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. Journal of Toxicological Sciences, 2017, 42, 343-348.	1.5	12
174	Cytochrome P450 2A6 Phenotyping Using Dietary Caffeine Salivary Metabolite Ratios and Genotyping Using Blood on Storage Cards in Non-smoking Japanese Volunteers. Drug Metabolism Letters, 2017, 10, 240-243.	0.8	4
175	Strong Induction of Cytochrome P450 1A/3A, But not P450 2B, in Cultured Hepatocytes from Common Marmosets and Cynomolgus Monkeys by Typical Human P450 Inducing Agents. Drug Metabolism Letters, 2017, 10, 244-253.	0.8	13
176	Effects of Meat Intake Frequency and Polymorphic Cytochrome P450 2A6 Activity on Individual Colorectal Tumour Risk in a Japanese Cohort. Journal of Cancer Therapy, 2017, 08, 645-652.	0.4	2
177	Utility of non-human primates in drug development: Comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. Biochemical Pharmacology, 2016, 121, 1-7.	4.4	67
178	Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors. Biopharmaceutics and Drug Disposition, 2016, 37, 310-313.	1.9	1
179	Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from nonâ€smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. Human Psychopharmacology, 2016, 31, 83-92.	1.5	11
180	Development of a genotyping tool for a functionally relevant <i>CYP2C19</i> allele (Phe100Asn, Ala103Val and Ile112Leu) in cynomolgus macaques. Journal of Veterinary Medical Science, 2016, 78, 147-148.	0.9	8

#	Article	IF	Citations
181	Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model. Scientific Reports, 2016, 6, 21419.	3.3	36
182	A New Marmoset P450 4F12 Enzyme Expressed in Small Intestines and Livers Efficiently Metabolizes Antihistaminic Drug Ebastine. Drug Metabolism and Disposition, 2016, 44, 833-841.	3.3	11
183	Structureâ€"Function Studies of Naphthalene, Phenanthrene, Biphenyl, and Their Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6. Chemical Research in Toxicology, 2016, 29, 1029-1040.	3.3	21
184	Marmoset cytochrome P450 2J2 mainly expressed in small intestines and livers effectively metabolizes human P450 2J2 probe substrates, astemizole and terfenadine. Xenobiotica, 2016, 46, 977-985.	1.1	13
185	Preâ€incubation with cyclosporine A potentiates its inhibitory effects on pitavastatin uptake mediated by recombinantly expressed cynomolgus monkey hepatic organic anion transporting polypeptide. Biopharmaceutics and Drug Disposition, 2016, 37, 479-490.	1.9	12
186	Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets. Biochemical Pharmacology, 2016, 120, 56-62.	4.4	14
187	Roles of Human CYP2A6 and Monkey CYP2A24 and 2A26 Cytochrome P450 Enzymes in the Oxidation of 2,5,2â€²,5â€²-Tetrachlorobiphenyl. Drug Metabolism and Disposition, 2016, 44, 1899-1909.	3.3	24
188	Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry. Chemical Research in Toxicology, 2016, 29, 1279-1281.	3.3	15
189	Physiologically based pharmacokineticâ€"pharmacodynamic modeling to predict concentrations and actions of sodiumâ€dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. Biopharmaceutics and Drug Disposition, 2016, 37, 491-506.	1.9	20
190	Whither the impending european regulation of presumed endocrine disruptors?. Regulatory Toxicology and Pharmacology, 2016, 82, A1-A2.	2.7	9
191	Upholding science in health, safety and environmental risk assessments and regulations. Toxicology, 2016, 371, 12-16.	4.2	7
192	In vivo individual variations in pharmacokinetics of efavirenz in cynomolgus monkeys genotyped for cytochrome P450 2C9. Biopharmaceutics and Drug Disposition, 2016, 37, 379-383.	1.9	9
193	Systematic approach to optimize a pretreatment method for ultrasensitive liquid chromatography with tandem mass spectrometry analysis of multiple target compounds in biological samples. Journal of Separation Science, 2016, 39, 3212-3220.	2.5	5
194	A Case of Delayed Emergence After Propofol Anesthesia. A & A Case Reports, 2016, 7, 243-246.	0.7	8
195	Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5. Human Psychopharmacology, 2016, 31, 93-102.	1.5	7
196	Individual Differences in Metabolic Clearance of S-Warfarin Efficiently Mediated by Polymorphic Marmoset Cytochrome P450 2C19 in Livers. Drug Metabolism and Disposition, 2016, 44, 911-915.	3.3	21
197	Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology. Chemical Research in Toxicology, 2016, 29, 1903-1911.	3.3	35
198	Analysis of gene expression for microminipig liver transcriptomes using parallel longâ€read technology and shortâ€read sequencing. Biopharmaceutics and Drug Disposition, 2016, 37, 220-232.	1.9	7

#	Article	IF	Citations
199	Oxidation of pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene by human cytochrome P450 2A13. Xenobiotica, 2016, 46, 211-224.	1.1	20
200	In vitroinhibition and enhancement of liver microsomal S-777469 metabolism by long-chain fatty acids and serum albumin: insight intoin vitroandin vivodiscrepancy of metabolite formation in humans. Xenobiotica, 2016, 46, 495-502.	1.1	3
201	Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling. Xenobiotica, 2016, 46, 759-764.	1.1	17
202	Genomic Landscape of Esophageal Squamous Cell Carcinoma inÂa Japanese Population. Gastroenterology, 2016, 150, 1171-1182.	1.3	265
203	Caffeine 7-N-demethylation andC-8-oxidation mediated by liver microsomal cytochrome P450 enzymes in common marmosets. Xenobiotica, 2016, 46, 573-578.	1.1	7
204	Functional polymerâ€dependent 3D culture accelerates the differentiation of HepaRG cells into mature hepatocytes. Hepatology Research, 2016, 46, 1045-1057.	3.4	50
205	Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica, 2016, 46, 1049-1055.	1.1	31
206	Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells. Xenobiotica, 2016, 46, 765-774.	1.1	19
207	Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica, 2016, 46, 163-168.	1.1	24
208	Analysis of six novel flavin-containing monooxygenase 3 (FMO3) gene variants found in a Japanese population suffering from trimethylaminuria. Molecular Genetics and Metabolism Reports, 2015, 5, 89-93.	1.1	10
209	Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations. Journal of Toxicological Sciences, 2015, 40, 33-42.	1.5	12
210	Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances. Biopharmaceutics and Drug Disposition, 2015, 36, 636-643.	1.9	7
211	Human pharmacokinetic profiling of the dipeptidyl peptidaseâ€IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. Biopharmaceutics and Drug Disposition, 2015, 36, 148-162.	1.9	9
212	Human HepaRG Cells can be Cultured in Hanging-drop Plates for Cytochrome P450 Induction and Function Assays. Drug Metabolism Letters, 2015, 9, 3-7.	0.8	10
213	Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam andR-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys usingin vitroâ€“in vivocorrelation. Xenobiotica, 2015, 45, 312-321.	1.1	24
214	Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo. Biochemical Pharmacology, 2015, 95, 110-114.	4.4	22
215	Dataset for genotyping validation of cytochrome P450 2A6 whole-gene deletion (CYP2A6 * 4) by real-time polymerase chain reaction platforms. Data in Brief, 2015, 5, 642-645.	1.0	6
216	Molecular Cloning, Tissue Distribution, and Functional Characterization of Marmoset Cytochrome P450 1A1, 1A2, and 1B1. Drug Metabolism and Disposition, 2015, 44, 8-15.	3.3	11

#	Article	IF	Citations
217	Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes. Clinica Chimica Acta, 2015, 441, 71-74.	1.1	10
218	Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metabolism Reviews, 2015, 47, 89-110.	3.6	98
219	Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes. Chemical Research in Toxicology, 2015, 28, 268-278.	3.3	17
220	CYP2D44 polymorphisms in cynomolgus and rhesus macaques. Molecular Biology Reports, 2015, 42, 1149-1155.	2.3	10
221	Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine. Xenobiotica, 2015, 45, 124-130.	1.1	14
222	Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica, 2015, 45, 881-886.	1.1	18
223	Evaluation of 89 Compounds for Identification of Substrates for Cynomolgus Monkey CYP2C76, a New Bupropion/Nifedipine Oxidase. Drug Metabolism and Disposition, 2015, 43, 27-33.	3.3	19
224	Human biofluid concentrations of mono(2-ethylhexyl)phthalate extrapolated from pharmacokinetics in chimeric mice with humanized liver administered with di(2-ethylhexyl)phthalate and physiologically based pharmacokinetic modeling. Environmental Toxicology and Pharmacology, 2015, 39, 1067-1073.	4.0	25
225	Azithromycin Can Prolong QT Interval and Suppress Ventricular Contraction, but Will Not Induce Torsade de Pointes. Cardiovascular Toxicology, 2015, 15, 232-240.	2.7	25
226	Substrate Selectivities and Catalytic Activities of Marmoset Liver Cytochrome P450 2A6 Differed from Those of Human P450 2A6. Drug Metabolism and Disposition, 2015, 43, 969-976.	3.3	19
227	Human urine and plasma concentrations of bisphenol A extrapolated from pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and semi-physiological pharmacokinetic modeling. Regulatory Toxicology and Pharmacology, 2015, 72, 71-76.	2.7	22
228	Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients. Journal of Cardiovascular Pharmacology, 2015, 65, 289-295.	1.9	65
229	Activation and Deactivation of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine by Cytochrome P450 Enzymes and Flavin-Containing Monooxygenases in Common Marmosets (Callithrix jacchus). Drug Metabolism and Disposition, 2015, 43, 735-742.	3.3	23
230	Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates,S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole. Drug Metabolism and Disposition, 2015, 43, 1408-1416.	3.3	41
231	Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase. Drug Metabolism and Disposition, 2015, 43, 1119-1122.	3.3	12
232	Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice. Chemical Research in Toxicology, 2015, 28, 2088-2090.	3.3	26
233	Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan. Xenobiotica, 2015, 45, 766-772.	1.1	26
234	Point mutation of cytochrome P450 2A6 (a polymorphic variant CYP2A6.25) confers new substrate specificity towards flavonoids. Biopharmaceutics and Drug Disposition, 2015, 36, 552-563.	1.9	6

#	Article	IF	Citations
235	Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients. Biochemical Pharmacology, 2015, 93, 104-109.	4.4	14
236	Zone analysis by two-dimensional electrophoresis with accelerator mass spectrometry of in vivo protein bindings of idiosyncratic hepatotoxicants troglitazone and flutamide bioactivated in chimeric mice with humanized liver. Toxicology Research, 2015, 4, 106-111.	2.1	12
237	Intravenous Administration of Apomorphine Does NOT Induce Long <scp>QT</scp> Syndrome: Experimental Evidence from In Vivo Canine Models. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 468-475.	2.5	8
238	Genetic polymorphism of cynomolgus and rhesus macaque CYP2C9. Drug Metabolism and Pharmacokinetics, 2015, 30, 130-132.	2.2	17
239	Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers. Drug Metabolism and Pharmacokinetics, 2015, 30, 70-74.	2.2	18
240	Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans. Drug Metabolism and Pharmacokinetics, 2015, 30, 64-69.	2.2	35
241	Drug Interactions between Nine Antifungal Agents and Drugs Metabolized by Human Cytochromes P450. Current Drug Metabolism, 2015, 15, 651-679.	1.2	97
242	Human Plasma Concentrations of Tolbutamide and Acetaminophen Extrapolated from <i>in vivo</i> Animal Pharmacokinetics Using <i>in vitro</i> Human Hepatic Clearances and Simple Physiologically Based Pharmacokinetic Modeling for Radio-labeled Microdose Clinical Studies. Radioisotopes, 2015, 64, 509-519.	0.2	7
243	Polymorphisms of CYP2D17 in Cynomolgus and Rhesus Macaques: an Evidence of the Genetic Basis for the Variability of CYP2D-Dependent Drug Metabolism. Drug Metabolism and Disposition, 2014, 42, 1407-1410.	3.3	17
244	Age-related pharmacokinetic changes of acetaminophen, antipyrine, diazepam, diphenhydramine, and ofloxacin in male cynomolgus monkeys and beagle dogs. Xenobiotica, 2014, 44, 893-901.	1.1	26
245	Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys. Xenobiotica, 2014, 44, 769-774.	1.1	12
246	The human hepatic cell line HepaRG as a possible cell source for the generation of humanized liver TK-NOG mice. Xenobiotica, 2014, 44, 146-153.	1.1	26
247	Relationships between flavinâ€containing monoâ€oxygenase 3 (<scp>FMO3</scp>) genotype and trimethylaminuria phenotype in a <scp>J</scp>apanese population. British Journal of Clinical Pharmacology, 2014, 77, 839-851.	2.4	18
248	Hepatic microsomal UDPâ€glucuronosyltransferase (UGT) activities in the microminipig. Biopharmaceutics and Drug Disposition, 2014, 35, 313-320.	1.9	20
249	Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica, 2014, 44, 242-253.	1.1	47
250	Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. Xenobiotica, 2014, 44, 10-16.	1.1	14
251	Evaluation of 23 Lots of Commercially Available Cryopreserved Hepatocytes for Induction Assays of Human Cytochromes P450. Drug Metabolism and Disposition, 2014, 42, 867-871.	3.3	27
252	Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype. Journal of Infectious Diseases, 2014, 209, 1941-1948.	4.0	88

#	Article	IF	Citations
253	Human Cytochrome P450 Oxidation of 5-Hydroxythalidomide and Pomalidomide, an Amino Analogue of Thalidomide. Chemical Research in Toxicology, 2014, 27, 147-156.	3.3	33
254	CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques. Biochemical Pharmacology, 2014, 91, 242-248.	4.4	31
255	Human plasma concentrations of herbicidal carbamate molinate extrapolated from the pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. Regulatory Toxicology and Pharmacology, 2014, 70, 214-221.	2.7	20
256	Thalidomide Increases Human Hepatic Cytochrome P450 3A Enzymes by Direct Activation of the Pregnane X Receptor. Chemical Research in Toxicology, 2014, 27, 304-308.	3.3	28
257	Pharmacokinetics and effects on serum cholinesterase activities of organophosphorus pesticides acephate and chlorpyrifos in chimeric mice transplanted with human hepatocytes. Regulatory Toxicology and Pharmacology, 2014, 70, 468-473.	2.7	22
258	Effect of Ketoconazole on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: An Open-Label Study in Healthy White Subjects in Germany. Clinical Therapeutics, 2014, 36, 760-769.	2.5	14
259	Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. Biochemical Pharmacology, 2014, 90, 159-165.	4.4	41
260	Trimethylamine generation in patients receiving hemodialysis treated with L-carnitine. CKJ: Clinical Kidney Journal, 2014, 7, 329-329.	2.9	7
261	Identification and Analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in Cynomolgus Macaques. Journal of Veterinary Medical Science, 2014, 76, 1647-1650.	0.9	16
262	Drug-induced Liver Toxicity Studies: Research into Human Metabolites Clarifies Their Role in Drug Development. Drug Metabolism and Pharmacokinetics, 2014, 29, 111.	2.2	2
263	Species, Ethnic, and Individual Differences in Human Drug-Metabolizing Cytochrome P450 P450 Enzymes. , 2014, , 293-305.		3
264	Qualitative De Novo Analysis of Full Length cDNA and Quantitative Analysis of Gene Expression for Common Marmoset (Callithrix jacchus) Transcriptomes Using Parallel Long-Read Technology and Short-Read Sequencing. PLoS ONE, 2014, 9, e100936.	2.5	29
265	Cardiohemodynamic and Electrophysiological Effects of Anti-influenza Drug Oseltamivir In Vivo and In Vitro. Cardiovascular Toxicology, 2013, 13, 234-243.	2.7	24
266	Molecular and functional characterization of flavin-containing monooxygenases in cynomolgus macaque. Biochemical Pharmacology, 2013, 85, 1837-1847.	4.4	28
267	Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. Regulatory Toxicology and Pharmacology, 2013, 65, 316-324.	2.7	28
268	Systematic identification and characterization of glutathione S-transferases in cynomolgus macaque. Biochemical Pharmacology, 2013, 86, 679-690.	4.4	17
269	Metabolic Activation of Polycyclic Aromatic Hydrocarbons and Aryl and Heterocyclic Amines by Human Cytochromes P450 2A13 and 2A6. Chemical Research in Toxicology, 2013, 26, 529-537.	3.3	52
270	Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition. Chemical Research in Toxicology, 2013, 26, 517-528.	3.3	31

#	Article	IF	Citations
271	Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities. Biochemical Pharmacology, 2013, 85, 1588-1593.	4.4	61
272	In Vivo Drug Interactions of the Teratogen Thalidomide with Midazolam: Heterotropic Cooperativity of Human Cytochrome P450 in Humanized TK-NOG Mice. Chemical Research in Toxicology, 2013, 26, 486-489.	3.3	40
273	Mechanism-based Inhibition of CYP1A1 and CYP3A4 by the Furanocoumarin Chalepensin. Drug Metabolism and Pharmacokinetics, 2013, 28, 229-238.	2.2	18
274	Stem cell self-renewal factors Bmi1 and HMGA2 in head and neck squamous cell carcinoma: clues for diagnosis. Laboratory Investigation, 2013, 93, 1331-1338.	3.7	34
275	Comparison of P450 Enzymes Between Cynomolgus Monkeys and Humans: P450 Identities, Protein Contents, Kinetic Parameters, and Potential for Inhibitory Profiles. Current Drug Metabolism, 2013, 14, 239-252.	1.2	21
276	Clinical Evidence of Pharmacokinetic Changes in Thalidomide Therapy. Drug Metabolism and Pharmacokinetics, 2013, 28, 38-43.	2.2	10
277	Characterization of Microsomal GlutathioneS-Transferases MGST1, MGST2, and MGST3 in Cynomolgus Macaque. Drug Metabolism and Disposition, 2013, 41, 1621-1625.	3.3	20
278	Pitavastatin as an In Vivo Probe for Studying Hepatic Organic Anion Transporting Polypeptide-Mediated Drugâ€“Drug Interactions in Cynomolgus Monkeys. Drug Metabolism and Disposition, 2013, 41, 1875-1882.	3.3	32
279	Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. Xenobiotica, 2013, 43, 1037-1042.	1.1	14
280	The <i>CYP3A4</i> intron 6 C>T polymorphism (<i>CYP3A4*22</i>) is associated with reduced CYP3A4 protein level and function in human liver microsomes. Journal of Toxicological Sciences, 2013, 38, 349-354.	1.5	70
281	Cytochrome P450 Metabolic Activities in the Small Intestine of Cynomolgus Macaques Bred in Cambodia, China, and Indonesia. Drug Metabolism and Pharmacokinetics, 2013, 28, 510-513.	2.2	1
282	Comparison of Catalytic Properties of Cytochromes P450 3A4 and 3A5 by Molecular Docking Simulation. Drug Metabolism Letters, 2013, 8, 43-50.	0.8	14
283	Effects of ADH1C, ALDH2, and CYP2A6 Polymorphisms on Individual Risk of Tobacco-Related Lung Cancer in Male Japanese Smokers. Journal of Cancer Therapy, 2013, 04, 29-35.	0.4	5
284	Drug Interactions Mediated by Drug-Metabolizing Enzymes. Japanese Journal of Clinical Pharmacology and Therapeutics, 2013, 44, 470-472.	0.1	0
285	Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles. Current Drug Metabolism, 2013, 14, 239-52.	1.2	20
286	Cytochrome P450 2A6 Phenotyping Based on Dietary Caffeine Intake in a Japanese Population of Non-smokers. Drug Metabolism Letters, 2012, 6, 67-72.	0.8	1
287	CYP2C76 Non-synonymous Variants in Cynomolgus and Rhesus Macaques. Drug Metabolism and Pharmacokinetics, 2012, 27, 344-348.	2.2	14
288	Expression Profile of Hepatic Genes in Cynomolgus Macaques Bred in Cambodia, China, and Indonesia: Implications for Cytochrome P450 Genes. Drug Metabolism and Pharmacokinetics, 2012, 27, 307-316.	2.2	12

#	Article	IF	Citations
289	Comparison of Cytochrome P450 2C Subfamily Members in Terms of Drug Oxidation Rates and Substrate Inhibition. Current Drug Metabolism, 2012, 13, 1145-1159.	1.2	18
290	Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. Journal of Toxicological Sciences, 2012, 37, 1157-1164.	1.5	33
291	Lung tumorigenesis promoted by anti-apoptotic effects of cotinine, a nicotine metabolite through activation of PI3K/Akt pathway. Journal of Toxicological Sciences, 2012, 37, 555-563.	1.5	44
292	Evaluation of cytotoxic potential of cored soft contact lenses with adsorbed active ingredients from over-the-counter eye drops. Journal of Toxicological Sciences, 2012, 37, 639-643.	1.5	2
293	Variants in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Molecular Genetics and Metabolism, 2012, 107, 330-334.	1.1	22
294	In Vivo Formation of Dihydroxylated and Glutathione Conjugate Metabolites Derived from Thalidomide and 5-Hydroxythalidomide in Humanized TK-NOG Mice. Chemical Research in Toxicology, 2012, 25, 274-276.	3.3	43
295	A rapid multiplex PCR assay that can reliably discriminate the cytochrome P450 2D6 whole-gene deletion allele from 2D6*10 alleles. Clinica Chimica Acta, 2012, 413, 1675-1677.	1.1	11
296	Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation. Biochemical Pharmacology, 2012, 84, 1691-1695.	4.4	21
297	Intravenous and oral administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid] produce thrombolysis through inhibition of plasma TAFIa in rats with tissue factor-induced microthrombosis. Thrombosis Research, 2012, 130, e222-e228.	1.7	7
298	Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 356-363.	1.5	16
299	Different Metabolites of Human Hepatotoxic Pyrazolopyrimidine Derivative 5â€nâ€Butylâ€Pyrazolo[1,5â€a]Pyrimidine Produced by Human, Rat and Monkey Cytochrome P450 1A2 and Liver Microsomes. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 405-408.	2.5	7
300	Cytochrome P450 2A6 Phenotyping Based on Dietary Caffeine Intake in a Japanese Population of Non-smokers. Drug Metabolism Letters, 2012, 6, 67-72.	0.8	1
301	Effect of Genetic Polymorphism of CYP2A6 on Individual Susceptibility to Colorectal Tumors in Japanese Smokers. Journal of Cancer Therapy, 2012, 03, 207-215.	0.4	4
302	Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metabolism Reviews, 2011, 43, 346-361.	3.6	101
303	Spectral Modification and Catalytic Inhibition of Human Cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by Four Chemopreventive Organoselenium Compounds. Chemical Research in Toxicology, 2011, 24, 1327-1337.	3.3	26
304	In Vivo Formation of a Glutathione Conjugate Derived from Thalidomide in Humanized uPA-NOG Mice. Chemical Research in Toxicology, 2011, 24, 287-289.	3.3	32
305	Direct genotyping of Cytochrome P450 2A6 whole gene deletion from human blood samples by the SmartAmp method. Clinica Chimica Acta, 2011, 412, 1249-1251.	1.1	10
306	Comparison of Cytochrome P450 2D6 and Variants in Terms of Drug Oxidation Rates and Substrate Inhibition. Current Drug Metabolism, 2011, 12, 412-435.	1.2	30

#	Article	IF	Citations
307	Species Difference between Cynomolgus Monkeys and Humans on Cytochromes P450 2D and 3A-Dependent Drug Oxidation Activities in Liver Microsomes. Journal of Health Science, 2011, 57, 164-170.	0.9	9
308	Drug Metabolism and Toxicity in Chimeric Mice with Humanized Liver. Journal of Health Science, 2011, 57, 22-27.	0.9	5
309	Microminipig, a Non-rodent Experimental Animal Optimized for Life Science Research: In Vivo Proarrhythmia Models of Drug-Induced Long QT Syndrome: Development of Chronic Atrioventricular Block Model of Microminipig. Journal of Pharmacological Sciences, 2011, 115, 122-126.	2.5	32
310	Cynomolgus Macaque CYP4 Isoforms Are Functional,Metabolizing Arachidonic Acid. Journal of Veterinary Medical Science, 2011, 73, 487-490.	0.9	8
311	CYP1B1 is Polymorphic in Cynomolgus and Rhesus Macaques. Journal of Veterinary Medical Science, 2011, 73, 1229-1231.	0.9	4
312	Discovery of Genetic Variants in CYP1D1: Implication for Functional Integrity of CYP1D1 in Cynomolgus Macaques and Rhesus Macaques. Drug Metabolism and Pharmacokinetics, 2011, 26, 627-631.	2.2	15
313	Expression of Cytochromes P450 in Fetal, Infant, and Juvenile Liver of Cynomolgus Macaques. Drug Metabolism and Pharmacokinetics, 2011, 26, 621-626.	2.2	8
314	Developmental variations in metabolic capacity of flavinâ€containing monoâ€oxygenase 3 in childhood. British Journal of Clinical Pharmacology, 2011, 71, 585-591.	2.4	24
315	Mechanismâ€based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. British Journal of Pharmacology, 2011, 163, 1250-1262.	5.4	18
316	Metabolism of P450 Probe Substrates by Cynomolgus Monkey CYP2C76. Basic and Clinical Pharmacology and Toxicology, 2011, 109, 315-318.	2.5	14
317	Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system. Journal of Bioscience and Bioengineering, 2011, 111, 78-84.	2.2	57
318	CYP1D1, pseudogenized in human, is expressed and encodes a functional drug-metabolizing enzyme in cynomolgus monkey. Biochemical Pharmacology, 2011, 81, 442-450.	4.4	41
319	Human Liver Enzymes Responsible for Metabolic Elimination of Tyramine, a Vasopressor Agent from Daily Food. Drug Metabolism Letters, 2011, 5, 216-219.	0.8	9
320	Comparison of the Inhibitory Profiles of Itraconazole and Cimetidine in Cytochrome P450 3A4 Genetic Variants. Drug Metabolism and Disposition, 2011, 39, 724-728.	3.3	24
321	Human Cytochrome P450 1A1 Is a Novel Target Gene of Liver X Receptor Î±. Drug Metabolism and Pharmacokinetics, 2011, 26, 451-457.	2.2	10
322	Stereoselectivity of Human Cytochrome P450 in Metabolic and Inhibitory Activities. Current Drug Metabolism, 2011, 12, 549-569.	1.2	23
323	CYP2G2, Pseudogenized in Human, Is Expressed in Nasal Mucosa of Cynomolgus Monkey and Encodes a Functional Drug-Metabolizing Enzyme. Drug Metabolism and Disposition, 2011, 39, 717-723.	3.3	14
324	Immunochemical Detection of Cytochrome P450 Enzymes in Liver Microsomes of 27 Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 654-661.	2.5	52

#	Article	IF	Citations
325	Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1â€²-Hydroxylation. Drug Metabolism and Disposition, 2011, 39, 757-762.	3.3	48
326	A Newly Developed DNA Microarray Is Useful to Assess Induction of Cytochromes P450 in the Cynomolgus Monkey. Drug Metabolism and Pharmacokinetics, 2011, 26, 228-235.	2.2	7
327	Individual Differences in Pharmacokinetics and Pharmacodynamics of Anesthetic Agent Propofol with Regard to CYP2B6 and UGT1A9 Genotype and Patient Age. Drug Metabolism and Pharmacokinetics, 2011, 26, 532-537.	2.2	33
328	Newly Identified CYP2C93 Is a Functional Enzyme in Rhesus Monkey, but Not in Cynomolgus Monkey. PLoS ONE, 2011, 6, e16923.	2.5	23
329	Two Naturally Occurring Terpenes, Dehydrocostuslactone and Costunolide, Decrease Intracellular GSH Content and Inhibit STAT3 Activation. PLoS ONE, 2011, 6, e20174.	2.5	84
330	Different Effects of <i>TERT</i>, <i>TP</i>63, and <i>CYP</i>2<i>A</i>6 Polymorphism on Individual Risk of Tobacco-Related Lung Cancer in Male Japanese Smokers. Journal of Cancer Therapy, 2011, 02, 690-696.	0.4	6
331	Methodologies for Investigating Drug Metabolism at the Early Drug Discovery Stage: Prediction of Hepatic Drug Clearance and P450 Contribution. Current Drug Metabolism, 2010, 11, 678-685.	1.2	59
332	Identification and Characterization of CYP2C18 in the Cynomolgus Macaque (Macaca fascicularis). Journal of Veterinary Medical Science, 2010, 72, 225-228.	0.9	10
333	Comparison of the Contributions of Cytochromes P450 3A4 and 3A5 in Drug Oxidation Rates and Substrate Inhibition. Journal of Health Science, 2010, 56, 239-256.	0.9	11
334	Blood Concentrations of 1,4-Dioxane in Humans after Oral Administration Extrapolated from In Vivo Rat Pharmacokinetics, In Vitro Human Metabolism, and Physiologically Based Pharmacokinetic Modeling. Journal of Health Science, 2010, 56, 557-565.	0.9	7
335	Human Blood Concentrations of Dichlorodiphenyltrichloroethane (DDT) Extrapolated from Metabolism in Rats and Humans and Physiologically Based Pharmacokinetic Modeling. Journal of Health Science, 2010, 56, 566-575.	0.9	24
336	Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population. European Journal of Clinical Pharmacology, 2010, 66, 1065-1068.	1.9	28
337	Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. Regulatory Toxicology and Pharmacology, 2010, 58, 252-258.	2.7	36
338	Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. British Journal of Clinical Pharmacology, 2010, 69, 593-597.	2.4	52
339	Biomonitoring of Urinary Cotinine Concentrations Associated with Plasma Levels of Nicotine Metabolites after Daily Cigarette Smoking in a Male Japanese Population. International Journal of Environmental Research and Public Health, 2010, 7, 2953-2964.	2.6	28
340	Human Blood Concentrations of Cotinine, a Biomonitoring Marker for Tobacco Smoke, Extrapolated from Nicotine Metabolism in Rats and Humans and Physiologically Based Pharmacokinetic Modeling. International Journal of Environmental Research and Public Health, 2010, 7, 3406-3421.	2.6	45
341	Alprazolam as an In Vivo Probe for Studying Induction of CYP3A in Cynomolgus Monkeys. Drug Metabolism and Disposition, 2010, 38, 1806-1813.	3.3	26
342	Genetic Variants ofCYP3A4andCYP3A5in Cynomolgus and Rhesus Macaques. Drug Metabolism and Disposition, 2010, 38, 209-214.	3.3	54

#	Article	IF	Citations
343	Cynomolgus Monkey CYP2D44 Newly Identified in Liver, Metabolizes Bufuralol, and Dextromethorphan. Drug Metabolism and Disposition, 2010, 38, 1486-1492.	3.3	37
344	Comparison of Cytochrome P450 3A Enzymes in Cynomolgus Monkeys and Humans. Drug Metabolism and Pharmacokinetics, 2010, 25, 388-391.	2.2	25
345	Approach for in Vivo Protein Binding of 5-n-Butyl-pyrazolo[1,5-a]pyrimidine Bioactivated in Chimeric Mice with Humanized Liver by Two-Dimensional Electrophoresis with Accelerator Mass Spectrometry. Chemical Research in Toxicology, 2010, 23, 152-158.	3.3	35
346	Structureâ^'Function Relationships of Inhibition of Human Cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 Flavonoid Derivatives. Chemical Research in Toxicology, 2010, 23, 1921-1935.	3.3	115
347	Human Liver Microsomal Cytochrome P450 3A Enzymes Involved in Thalidomide 5-Hydroxylation and Formation of a Glutathione Conjugate. Chemical Research in Toxicology, 2010, 23, 1018-1024.	3.3	46
348	A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin. Xenobiotica, 2010, 40, 621-629.	1.1	24
349	Drug Interactions of Thalidomide with Midazolam and Cyclosporine A: Heterotropic Cooperativity of Human Cytochrome P450 3A5. Drug Metabolism and Disposition, 2009, 37, 18-23.	3.3	43
350	Cloning, Expression, and Characterization of CYP3A43 in Cynomolgus Macaque (Macaca fascicularis). Drug Metabolism Letters, 2009, 3, 228-233.	0.8	10
351	Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding. Xenobiotica, 2009, 39, 227-235.	1.1	36
352	Two Novel CYP2D6*10 Haplotypes As Possible Causes of a Poor Metabolic Phenotype in Japanese. Drug Metabolism and Disposition, 2009, 37, 699-701.	3.3	34
353	Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica, 2009, 39, 795-802.	1.1	50
354	Human Cytochrome P450 1A2 Involvement in the Formation of Reactive Metabolites from a Species-Specific Hepatotoxic Pyrazolopyrimidine Derivative, 5-n-Butyl-7-(3,4,5-trimethoxybenzoylamino)pyrazolo[1,5-a]pyrimidine. Chemical Research in Toxicology, 2009, 22, 323-331.	3.3	26
355	Reverse Type I Binding Spectra of Human Cytochrome P450 1B1 Induced by Flavonoid, Stilbene, Pyrene, Naphthalene, Phenanthrene, and Biphenyl Derivatives That Inhibit Catalytic Activity: A Structureâ^'Function Relationship Study. Chemical Research in Toxicology, 2009, 22, 1325-1333.	3.3	39
356	Identification and Characterization of CYP2B6 cDNA in Cynomolgus Macaques (Macaca fascicularis). Journal of Veterinary Medical Science, 2009, 71, 1653-1656.	0.9	10
357	Pharmacokinetic Investigation of Increased Efficacy Against Malignant Gliomas of Carboplatin Combined With Hyperbaric Oxygenation. Neurologia Medico-Chirurgica, 2009, 49, 193-197.	2.2	12
358	Bonitos with Low Content of Malodorous Trimethylamine as Palliative Care for Self-reported Japanese Trimethylaminuria Subjects. Drug Metabolism and Pharmacokinetics, 2009, 24, 549-552.	2.2	11
359	Dose-dependent Effects of Cigarette Smoke on Blood Biomarkers in Healthy Japanese Volunteers: Observations from Smoking and Non-smoking. Journal of Health Science, 2009, 55, 259-264.	0.9	16
360	Genetic Polymorphisms of Glycine N-acyltransferase in Japanese Individuals. Drug Metabolism and Pharmacokinetics, 2009, 24, 114-117.	2.2	14

#	Article	IF	Citations
361	Inter-individual Variation in Flavin-containing Monooxygenase 3 in Livers from Japanese: Correlation with Hepatic Transcription Factors. Drug Metabolism and Pharmacokinetics, 2009, 24, 218-225.	2.2	27
362	Cytochrome P450-depedent Drug Oxidation Activity of Liver Microsomes from Microminipigs, A Possible New Animal Model for Humans in Non-clinical Studies. Drug Metabolism and Pharmacokinetics, 2009, 24, 404-408.	2.2	41
363	Oxidation of Endobiotics Mediated by Xenobiotic-Metabolizing Forms of Human Cytochrome P450. Current Drug Metabolism, 2009, 10, 700-712.	1.2	36
364	Effects of Histidine-Tag on Recombinant Human Cytochrome P450 3A5 Catalytic Activity in Reconstitution Systems. Drug Metabolism Letters, 2009, 3, 207-211.	0.8	9
365	Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. British Journal of Clinical Pharmacology, 2008, 65, 437-439.	2.4	99
366	Individual Differences in Toxicological Response Caused by a Diversity of Chemicals: Observations in Japan. Chemical Research in Toxicology, 2008, 21, 3-4.	3.3	2
367	Human Cytochrome P450 2A13 Efficiently Metabolizes Chemicals in Air Pollutants: Naphthalene, Styrene, and Toluene. Chemical Research in Toxicology, 2008, 21, 720-725.	3.3	66
368	Interaction of Polycyclic Aromatic Hydrocarbons with Human Cytochrome P450 1B1 in Inhibiting Catalytic Activity. Chemical Research in Toxicology, 2008, 21, 2313-2323.	3.3	34
369	Increased transendothelial permeability of anti-cancer agent carboplatin with the aid of hyperbaric oxygenation. Xenobiotica, 2008, 38, 1298-1304.	1.1	3
370	Increased distribution of carboplatin, an anti-cancer agent, to rat brains with the aid of hyperbaric oxygenation. Xenobiotica, 2008, 38, 1471-1475.	1.1	7
371	Comparison of Kinetic Parameters for Drug Oxidation Rates and Substrate Inhibition Potential Mediated by Cytochrome P450 3A4 and 3A5. Current Drug Metabolism, 2008, 9, 20-33.	1.2	78
372	Effects of Enzyme Sources on Midazolam 1-Hydroxylation Activity Catalyzed by Recombinant Cytochrome P450 3A4 in Combination with NADPH-Cytochrome P450 Reductase. Drug Metabolism Letters, 2008, 2, 190-192.	0.8	8
373	Complex Mechanism Underlying Transcriptional Control of the Haplotyped Flavin-containing Monooxygenase 3 (FMO3) Gene in Japanese: Different Regulation between Mutations in 5â€²-Upstream Distal Region and Common Element in Proximal Region. Drug Metabolism and Pharmacokinetics, 2008, 23, 54-58.	2.2	14
374	Heterotropic Cooperativity in Oxidation Mediated by Cytochrome P450. Current Drug Metabolism, 2008, 9, 453-462.	1.2	56
375	Effect of Genetic Variants of the Human Flavin-Containing Monooxygenase 3 on N- and S-Oxygenation Activities. Drug Metabolism and Disposition, 2007, 35, 328-330.	3.3	55
376	Involvement of human cytochrome P450 2B6 in theÏ‰- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica, 2007, 37, 717-724.	1.1	14
377	Genetic Polymorphism of the Flavin-Containing Monooxygenase 3 (FMO3) Associated with Trimethylaminuria (Fish Odor Syndrome): Observations from Japanese Patients. Current Drug Metabolism, 2007, 8, 487-491.	1.2	36
378	Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes. Drug Metabolism and Disposition, 2007, 35, 1733-1736.	3.3	15

#	Article	IF	Citations
379	Genetic Polymorphism of Bile acid CoA: Amino acid N-acyltransferase in Japanese Individuals. Drug Metabolism and Pharmacokinetics, 2007, 22, 125-128.	2.2	4
380	Missense and Nonsense Mutations of the Flavin-containing Monooxygenase 3 Gene in a Japanese Cohort. Drug Metabolism and Pharmacokinetics, 2007, 22, 61-64.	2.2	14
381	Pharmacokinetics of Antifungal Agent Micafungin in Critically Ill Patients Receiving Continuous Hemodialysis Filtration. Yakugaku Zasshi, 2007, 127, 897-901.	0.2	55
382	Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenetics and Genomics, 2007, 17, 827-839.	1.5	33
383	Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Molecular Genetics and Metabolism, 2007, 90, 58-63.	1.1	41
384	Different Mechanisms for Inhibition of Human Cytochromes P450 1A1, 1A2, and 1B1 by Polycyclic Aromatic Inhibitors. Chemical Research in Toxicology, 2007, 20, 489-496.	3.3	58
385	Effects of Propofol Analogs on Glucuronidation of Propofol, an Anesthetic Drug, by Human Liver Microsomes. Drug Metabolism Letters, 2007, 1, 77-79.	0.8	11
386	Transient trimethylaminuria related to menstruation. BMC Medical Genetics, 2007, 8, 2.	2.1	62
387	Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochemical Pharmacology, 2007, 73, 2020-2026.	4.4	119
388	Genotoxic Activation of the Environmental Pollutant 3-Nitrobenzanthrone by Human Cytochrome P450 Enzymes Expressed in Salmonella typhimurium umu Tester Strains. Genes and Environment, 2007, 29, 146-152.	2.1	3
389	Cytochrome P450 Reconstitution Systems. , 2006, 320, 61-72.		9
390	Prediction ofin vivodrug clearance fromin vitrodata. II: Potential inter-ethnic differences. Xenobiotica, 2006, 36, 499-513.	1.1	83
391	Species differences in hydrolase activities toward OT-7100 responsible for different bioavailability in rats, dogs, monkeys and humans. Xenobiotica, 2006, 36, 301-314.	1.1	9
392	Activities of Rat Cytochrome P450 3A and 2C Isoforms are Increased In Vivo by Magnesium Sulfate as Evidenced by Enhanced Oxidation of Bupivacaine and Testosterone in Liver Microsomes. Drug Metabolism and Pharmacokinetics, 2006, 21, 201-207.	2.2	4
393	High-performance Liquid Chromatographic Assay for Carboplatin in Ultrafiltered Plasma Combined with Hyperbaric Oxygenation. Drug Metabolism and Pharmacokinetics, 2006, 21, 429-431.	2.2	5
394	CYP2A13 expressed in human bladder metabolically activates 4â€aminobiphenyl. International Journal of Cancer, 2006, 119, 2520-2526.	5.1	61
395	Three Novel Single Nucleotide Polymorphisms of the FMO3 Gene in a Japanese Population. Drug Metabolism and Pharmacokinetics, 2006, 21, 245-247.	2.2	18
396	In vivo Evaluation of Coumarin and Nicotine as Probe Drugs to Predict the Metabolic Capacity of CYP2A6 Due to Genetic Polymorphism in Thais. Drug Metabolism and Pharmacokinetics, 2006, 21, 475-484.	2.2	38

#	Article	IF	Citations
397	Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica, 2006, 36, 1201-1209.	1.1	41
398	Rat Cytochrome P450 2C11 in Liver Microsomes Involved in Oxidation of Anesthetic Agent Propofol and Deactivated by Prior Treatment with Propofol. Drug Metabolism and Disposition, 2006, 34, 1803-1805.	3.3	27
399	High prevalence of cytochrome P 450 2A6*1A alleles in a black African population of Ghana. European Journal of Clinical Pharmacology, 2005, 60, 855-857.	1.9	33
400	Sexual behaviour and high risk human papillomavirus infections in Japanese women. Sexually Transmitted Infections, 2005, 81, 280-282.	1.9	7
401	CYP2A6 IS A PRINCIPAL ENZYME INVOLVED IN HYDROXYLATION OF 1,7-DIMETHYLXANTHINE, A MAIN CAFFEINE METABOLITE, IN HUMANS. Drug Metabolism and Disposition, 2005, 33, 1361-1366.	3.3	29
402	Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. Carcinogenesis, 2005, 26, 1947-1955.	2.8	44
403	Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers. Xenobiotica, 2005, 35, 69-83.	1.1	62
404	Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2005, 581, 165-171.	1.7	24
405	Mild trimethylaminuria observed in a Japanese cohort with liver damage. American Journal of Medicine, 2005, 118, 803-805.	1.5	16
406	Identification of a Novel Polymorphic Enhancer of the Human CYP3A4 Gene. Molecular Pharmacology, 2004, 65, 326-334.	2.3	94
407	Distinct ontogenic and regional expressions of newly identified Cajal-Retzius cell-specific genes during neocorticogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 14509-14514.	7.1	76
408	Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis, 2004, 25, 2451-2458.	2.8	178
409	CYP3A5 Contributes Significantly to CYP3A-mediated Drug Oxidations in Liver Microsomes from Japanese Subjects. Drug Metabolism and Pharmacokinetics, 2004, 19, 120-129.	2.2	47
410	Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes. Biochemical Pharmacology, 2004, 67, 1269-1278.	4.4	29
411	Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2004, 562, 151-162.	1.7	26
412	Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients. Life Sciences, 2004, 74, 2739-2747.	4.3	62
413	Effects of cytochrome b5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochemical Pharmacology, 2003, 66, 2333-2340.	4.4	55
414	Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes. Xenobiotica, 2003, 33, 43-55.	1.1	33

#	Article	IF	Citations
415	Novel Nonsynonymous Polymorphisms of the CYP1A1 Gene in Japanese. Drug Metabolism and Pharmacokinetics, 2003, 18, 218-221.	2.2	4
416	Two Novel Haplotypes of CYP2D6 Gene in a Japanese Population. Drug Metabolism and Pharmacokinetics, 2003, 18, 269-271.	2.2	31
417	Eighteen Novel Polymorphisms of the CYP2A13 Gene in Japanese. Drug Metabolism and Pharmacokinetics, 2003, 18, 86-90.	2.2	21
418	Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics and Genomics, 2003, 13, 689-695.	5.7	67
419	Two Novel Single Nucleotide Polymorphisms (SNPs) of the FMO3 Gene in Japanese. Drug Metabolism and Pharmacokinetics, 2003, 18, 333-335.	2.2	28
420	Aryl hydrocarbon hydroxylase represents CYP1B1, and not CYP1A1, in human freshly isolated white cells: trimodal distribution of Japanese population according to induction of CYP1B1 mRNA by environmental dioxins. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 219-22.	2.5	5
421	Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Cancer Research, 2003, 63, 7581-3.	0.9	56
422	Formation of a Novel Quinone Epoxide Metabolite of Troglitazone with Cytotoxic to HepG2 Cells. Drug Metabolism and Disposition, 2002, 30, 155-160.	3.3	84
423	Hepatocyte Nuclear Factor-1Î± Is a Causal Factor Responsible for Interindividual Differences in the Expression of UDP-Glucuronosyltransferase 2B7 mRNA in Human Livers. Drug Metabolism and Disposition, 2002, 30, 613-615.	3.3	41
424	A Major Genotype in UDP-glucuronosyltransferase 2B15. Drug Metabolism and Pharmacokinetics, 2002, 17, 164-166.	2.2	4
425	CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. Carcinogenesis, 2002, 23, 595-598.	2.8	56
426	Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. Pharmacogenetics and Genomics, 2002, 12, 241-249.	5.7	34
427	A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics and Genomics, 2002, 12, 299-306.	5.7	126
428	Novel Mutations of the CYP2A6 Gene in a Thai Population with Lowered Capacity of Coumarin 7-Hydroxylation. Drug Metabolism and Pharmacokinetics, 2002, 17, 161-163.	2.2	4
429	Activities of Cytochrome P450 Enzymes in Liver and Kidney Microsomes from Systemic Carnitine Deficiency Mice with a Gene Mutation of Carnitine/Organic Cation Transporter. Drug Metabolism and Pharmacokinetics, 2002, 17, 47-53.	2.2	5
430	Twenty One Novel Single Nucleotide Polymorphisms (SNPs) of the CYP2A6 Gene in Japanese and Caucasians. Drug Metabolism and Pharmacokinetics, 2002, 17, 482-487.	2.2	32
431	Roles of NADPH-P450 Reductase and Apo- and Holo-Cytochrome b5 on Xenobiotic Oxidations Catalyzed by 12 Recombinant Human Cytochrome P450s Expressed in Membranes of Escherichia coli. Protein Expression and Purification, 2002, 24, 329-337.	1.3	224
432	Genotoxic activation of benzophenone and its two metabolites by human cytochrome P450s in SOS/umu assay. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2002, 519, 199-204.	1.7	22

#	Article	IF	Citations
433	Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes. Biochemical Pharmacology, 2002, 63, 2081-2090.	4.4	9
434	Evaluation of Approach to Predict the Contribution of Multiple Cytochrome P450s in Drug Metabolism Using Relative Activity Factor: Effects of the Differences in Expression Levels of NADPHâ€“Cytochrome P450 Reductase and Cytochrome b5 in the Expression System and the Differences in the Marker Activities. Journal of Pharmaceutical Sciences, 2002, 91, 952-963.	3.3	46
435	A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test*. Clinical Pharmacology and Therapeutics, 2002, 72, 200-208.	4.7	44
436	Metabolic activation of carcinogenic 1-nitropyrene by human cytochrome P450 1B1 in Salmonella typhimurium strain expressing an O-acetyltransferase in SOS/umu assay. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2001, 497, 223-233.	1.7	22
437	Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sciences, 2001, 70, 471-482.	4.3	87
438	Characterization of (??)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics and Genomics, 2001, 11, 143-156.	5.7	54
439	Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics and Genomics, 2001, 11, 317-323.	5.7	88
440	Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. International Journal of Cancer, 2001, 94, 222-227.	5.1	41
441	Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clinical Pharmacology and Therapeutics, 2001, 69, 72-78.	4.7	140
442	Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. European Journal of Pharmaceutical Sciences, 2001, 12, 505-513.	4.0	75
443	Stimulation of Cytochrome P450 Reactions by Apo-cytochromeb 5. Journal of Biological Chemistry, 2001, 276, 30885-30891.	3.4	94
444	Cooperativity ofÎ±-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica, 2001, 31, 265-275.	1.1	26
445	Induction of cytochrome P450 1B1 in lung, liver and kidney of rats exposed to diesel exhaust. Carcinogenesis, 2001, 22, 2033-2038.	2.8	32
446	Carcinoma of tongue in a patient with Fanconi's anemia.. Nihon Koku Geka Gakkai Zasshi, 2001, 47, 567-570.	0.0	3
447	DELINEATION OF THE SURGICAL MARGINS OF SOFT TISSUE IN THE SURGICAL PROCEDURE FOR GINGIVAL CANCER OF MANDIBLE, BASED ON THE DEPTH OF INVASION. Japanese Jornal of Head and Neck Cancer, 2001, 27, 38-43.	0.1	0
448	Inhibitory effects of amiodarone and its N -deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions. British Journal of Clinical Pharmacology, 2000, 49, 244-253.	2.4	170
449	Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharmaceutical Research, 2000, 17, 1189-1197.	3.5	78
450	Characterization of liver microsomal 7-ethoxycoumarin O -deethylation and chlorzoxazone 6-hydroxylation activities in Japanese and Caucasian subjects genotyped for CYP2E1 gene. Archives of Toxicology, 2000, 74, 372-378.	4.2	16

#	Article	IF	Citations
451	CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Archives of Toxicology, 2000, 73, 532-539.	4.2	60
452	A new PCR-based assay amplifies the E6â€“E7 genes of most mucosal human papillomaviruses (HPV). Virus Research, 2000, 67, 127-139.	2.2	46
453	Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2000, 472, 129-138.	1.7	56
454	A case of adenoid cystic carcinoma arising at the circumvallate papilla of the tongue.. Nihon Koku Geka Gakkai Zasshi, 2000, 46, 775-777.	0.0	1
455	HYPERCALCEMIA IN PATIENTS WITH ORAL CANCER. Japanese Jornal of Head and Neck Cancer, 2000, 26, 95-100.	0.1	5
456	Role of human N-acetyltransferases, NAT1 or NAT2, in genotoxicity of nitroarenes and aromatic amines in Salmonella typhimurium NM6001 and NM6002. Carcinogenesis, 1999, 20, 1079-1083.	2.8	23
457	Molecular Cloning of a Novel Human Collectin from Liver (CL-L1). Journal of Biological Chemistry, 1999, 274, 13681-13689.	3.4	126
458	Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes. Biomedical Applications, 1999, 721, 13-19.	1.7	53
459	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of Toxicology, 1999, 73, 65-70.	4.2	209
460	Phospholipase D Activity of Cytochrome P450 in Human Liver Endoplasmic Reticulum. Archives of Biochemistry and Biophysics, 1999, 367, 81-88.	3.0	29
461	Comparative Studies on the Catalytic Roles of Cytochrome P450 2C9 and Its Cys- and Leu-Variants in the Oxidation of Warfarin, Flurbiprofen, and Diclofenac by Human Liver Microsomes. Biochemical Pharmacology, 1998, 56, 243-251.	4.4	153
462	Activation and detoxication of aflatoxin B1. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 402, 121-128.	1.0	271
463	Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. , 1998, 75, 529-535.		46
464	Human papillomavirus,Chlamydia trachomatis, and other risk factors associated with cervical cancer in China. International Journal of Clinical Oncology, 1998, 3, 81-87.	2.2	6
465	Selectivity of Polycyclic Inhibitors for Human Cytochrome P450s 1A1, 1A2, and 1B1. Chemical Research in Toxicology, 1998, 11, 1048-1056.	3.3	198
466	Roles of Cytochromes P450 1A2 and 3A4 in the Oxidation of Estradiol and Estrone in Human Liver Microsomes. Chemical Research in Toxicology, 1998, 11, 659-665.	3.3	171
467	Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica, 1998, 28, 103-115.	1.1	53
468	Cytochrome P450 Reconstitution Systems. , 1998, 107, 85-94.		12

#	Article	IF	Citations
469	Linkage between the distribution of mutations in theCYP2C18andCYP2C19genes in the Japanese and Caucasian. Xenobiotica, 1998, 28, 403-411.	1.1	11
470	AFLATOXIN B1 OXIDATION BY HUMAN CYTOCHROME P450s. Journal of Toxicological Sciences, 1998, 23, 132-135.	1.5	2
471	Immunoglobulinâ€A and â€G responses against virusâ€like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intraâ€epithelial lesions. International Journal of Cancer, 1998, 75, 529-535.	5.1	2
472	Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4???-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics and Genomics, 1997, 7, 103-113.	5.7	130
473	Aflatoxin B1 8,9-Epoxide Hydrolysis in the Presence of Rat and Human Epoxide Hydrolase. Chemical Research in Toxicology, 1997, 10, 672-676.	3.3	57
474	Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochemical Pharmacology, 1997, 54, 1195-1203.	4.4	129
475	Reconstitution of Recombinant Cytochrome P450 2C10(2C9) and Comparison with Cytochrome P450 3A4 and Other Forms: Effects of Cytochrome P450â€“P450 and Cytochrome P450â€“b5Interactions. Archives of Biochemistry and Biophysics, 1997, 342, 329-337.	3.0	127
476	Progesterone and Testosterone Hydroxylation by Cytochromes P450 2C19, 2C9, and 3A4 in Human Liver Microsomes. Archives of Biochemistry and Biophysics, 1997, 346, 161-169.	3.0	283
477	O I.4 Roles of human cytochrome P450s 1A1, 1A2, 1B1, 2E1, and 3A4/5/7 in the activation of environmental procarcinogens and promutagens. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 379, S6.	1.0	2
478	Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Archives of Toxicology, 1997, 71, 401-408.	4.2	166
479	OMEPRAZOLE HYDROXYLATION BY CYP2C19 AND CYP3A4: PREDICTION TOWARDS HUMAN LIVER ACTIVITIES USING THE DATA OF RECOMBINANT P450 ENZYMES. Drug Metabolism and Pharmacokinetics, 1997, 12, 120-121.	0.0	0
480	Activation and Inactivation of Carcinogenic Dihaloalkanes and Other Compounds by Glutathione S-Transferase 5-5 in Salmonella typhimurium Tester Strain NM5004. Chemical Research in Toxicology, 1996, 9, 333-340.	3.3	37
481	7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochemical Pharmacology, 1996, 51, 313-319.	4.4	88
482	Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes. Biochemical Pharmacology, 1996, 52, 301-309.	4.4	69
483	Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes. Archives of Biochemistry and Biophysics, 1996, 325, 174-182.	3.0	130
484	Recombinant Human Cytochrome P450 1A2 and an N-Terminal-Truncated Form: Construction, Purification, Aggregation Properties, and Interactions with Flavodoxin, Ferredoxin, and NADPH-Cytochrome P450 Reductase. Archives of Biochemistry and Biophysics, 1996, 327, 11-19.	3.0	66
485	High Rates of Substrate Hydroxylation by Human Cytochrome P450 3A4 in Reconstituted Membranous Vesicles: Influence of Membrane Charge. Biochemical and Biophysical Research Communications, 1996, 221, 318-322.	2.1	50
486	Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes.. Journal of Toxicological Sciences, 1996, 21, 215-226.	1.5	16

#	Article	IF	Citations
487	Lack of Electron Transfer from Cytochrome b5 in Stimulation of Catalytic Activities of Cytochrome P450 3A4. Journal of Biological Chemistry, 1996, 271, 27438-27444.	3.4	159
488	A new Salmonella typhimurium NM5004 strain expressing rat glutathione S-transferase 5â€“5: use in detection of genotoxicity of dihaloalkanes using an SOS/umu test system. Carcinogenesis, 1996, 17, 297-302.	2.8	37
489	Metabolic Activation of Chrysene by Human Hepatic and Pulmonary Cytochrome P450 Enzymes. Polycyclic Aromatic Compounds, 1996, 10, 59-66.	2.6	3
490	Involvement of Cytochrome P450, Glutathione S-Transferase, and Epoxide Hydrolase in the Metabolism of Aflatoxin B 1 and Relevance to Risk of Human Liver Cancer. Environmental Health Perspectives, 1996, 104, 557.	6.0	63
491	Activation of Toxic Chemicals by Cytochrome P450 Enzymes. Advances in Experimental Medicine and Biology, 1996, 387, 7-15.	1.6	11
492	Development of high sensitive umu test system: rapid detection of genotoxicity of promutagenic aromatic amines by Salmonella typhimurium strain NM2009 possessing high O-acetyltransferase activity. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1995, 334, 145-156.	0.4	84
493	Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes. Carcinogenesis, 1995, 16, 2167-2170.	2.8	55
494	Roles of Divalent Metal Ions in Oxidations Catalyzed by Recombinant Cytochrome P450 3A4 and Replacement of NADPH-Cytochrome P450 Reductase with Other Flavoproteins, Ferredoxin, and Oxygen Surrogates. Biochemistry, 1995, 34, 8380-8389.	2.5	137
495	Expression of Cytochrome-P450-3A5 in Escherichia Coli: Effects of 5â€² Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities. Archives of Biochemistry and Biophysics, 1995, 317, 374-384.	3.0	144
496	Mutagenic Activation of 3-Methoxy-4-aminoazobenzene by Mouse Renal Cytochrome-P450 CYP4B1: Cloning and Characterization of Mouse CYP4B1. Archives of Biochemistry and Biophysics, 1995, 321, 255-262.	3.0	40
497	Oxidation of Aflatoxin B1 by Bacterial Recombinant Human Cytochrome P450 Enzymes. Chemical Research in Toxicology, 1995, 8, 218-225.	3.3	208
498	Activation of trans-l,2-dihydro-l,2-dihydroxy-6-aminochrysene to genotoxic metabolites by rat and human cytochromes P450. Carcinogenesis, 1994, 15, 465-470.	2.8	13
499	Fluorescencein situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1. Japanese Journal of Human Genetics, 1994, 39, 337-343.	0.8	17
500	Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes. Biochemical Pharmacology, 1994, 47, 1957-1963.	4.4	21
501	Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochemical Pharmacology, 1994, 47, 727-735.	4.4	117
502	Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7Î±- and coumarin 7-hydroxylations. Biochemical Pharmacology, 1994, 48, 1524-1527.	4.4	43
503	Highly sensitiveumu test system for the detection of mutagenic nitroarenes inSalmonella typhimurium NM3009 having high O-acetyltransferase and nitroreductase activities. Environmental and Molecular Mutagenesis, 1993, 21, 357-364.	2.2	65
504	Roles of different forms of cytochrome P450 in the activation of the promutagen 6-aminochrysene to genotoxic metabolites in human liver microsomes. Carcinogenesis, 1993, 14, 1271-1278.	2.8	36

#	Article	IF	Citations
505	Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylainine to products genotoxic in an acetyltransferaseâ€“overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis, 1992, 13, 979-985.	2.8	94
506	Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 1992, 13, 1789-1794.	2.8	369
507	Cytochrome P-450 forms and its inducibility by PCB isomers in black-headed gulls and black-tailed gulls. Marine Pollution Bulletin, 1992, 24, 316-321.	5.0	24
508	Rat pulmonary microsomal cytochrome P-450 enzymes involved in the activation of procarcinogens. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1992, 284, 233-241.	1.0	18
509	Use of a newly developed tester strain Salmonella typhimurium NM2009 for the study of metabolic activation of carcinogenic aromatic amines by rat liver microsomal cytochrome P-450 enzymes. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1992, 272, 183-192.	0.4	24
510	Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescencein situ hybridization. Japanese Journal of Human Genetics, 1992, 37, 133-138.	0.8	53
511	Roles of different cytochrome P450 enzymes in bioactivation of the potent hepatocarcinogen 3-methoxy-4-aminoazobenzene by rat and human liver microsomes. Carcinogenesis, 1991, 12, 133-139.	2.8	20
512	Metabolic deactivation of furylfuramide by cytothrome P450 in human and liver microsomes. Carcinogenesis, 1990, 11, 103-110.	2.8	12
513	The evaluation of genotoxic activities of disinfectants and their metabolites by umu test. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1988, 209, 155-160.	1.1	49
514	Mutagenicity of N-nitrosodiethanolamine in the Salmonella/microsome test. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1987, 192, 91-94.	1.1	4
515	Activation of carcinogenic N-nitrosopropylamines to mutagens by lung and pancreas S9 fractions from various animal species and man. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1986, 160, 159-169.	1.0	9
516	Inhibitory effect of organic solvents on the mutagenicity of N-nitrosodialkylamines in Salmonella. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1985, 142, 153-158.	1.1	27
517	Genotoxicity of carcinogenic N-nitrosopropylamine derivatives in the hepatocyte primary culture/DNA-repair test. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1985, 144, 197-202.	1.1	11
518	Mutagenic activation of carcinogenic N-nitrosopropylamines by rat liver: evidence for a cytochrome P-450 dependent reaction. Carcinogenesis, 1985, 6, 415-420.	2.8	38
519	Distribution, metabolism and excretion of N-nitrosobis(2-hydroxypropyl)amine in Wistar rats. Carcinogenesis, 1984, 5, 1443-1448.	2.8	16
520	Influence of microsomal and cytosolic fractions from the liver of 4 animal species and man on the mutagenicity of carcinogenic aminoazo dyes and nature of the mutagenicity-enhancing factor in the cytosol from rat liver.. Chemical and Pharmaceutical Bulletin, 1984, 32, 3641-3650.	1.3	7
521	Clinical use and evaluation of nonsteroid analgesic antiinflammatory agent, 16091 R. P.(Metiazinic) Tj ETQq1 1 0.784314 rgBT /Overl	0.0	0
522	Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies. Annals of Hematology, 0, , .	1.8	0